Antisense compounds, compositions and methods are provided for modulating the expression of TERT. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TERT. Methods of using these compounds for modulation of TERT expression and for treatment of diseases associated with expression of TERT are provided.
Claims What is claimed is: 1. A compound 8-50 nucleobases in length wherein the compound has a sequence comprising at least an 8-nucleobase portion of SEQ ID NO: 43, 44, 46, 47, 48, 49, 50, 52, 53, 54, 58, 59, 60, 61, 64, 65, 68, 69, 70, 76, 77, 80, 83, 85, 86, 87, 89, 90, 91, 92, 93, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 106, 107 or 108 and wherein said compound specifically hybridizes with and inhibits the expression of TERT. 2. The compound of claim 1 which is an antisense oligonucleotide. 3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 4. The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage. 5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 6. The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 8. The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine. 9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 10. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 11. The composition of claim 10 further comprising a colloidal dispersion system. 12. The composition of claim 10 wherein the compound is an antisense oligonucleotide. 13. A method of inhibiting the expression of TERT in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 1 so that expression of TERT is inhibited. 14. A method of modulating apoptosis in a cell comprising contacting said cell in vitro with the compound of claim 1, whereby apoptosis is modulated. 15. A method of inhibiting cell growth comprising contacting a cell in vitro with the compound of claim 1, whereby the growth of the cell is inhibited. 16. The method of claim 15 wherein said cells are cancer cells. 17. A compound which has a sequence consisting of SEQ ID NO: 57, 66, 67 or 71. 18. The compound of claim 17 which is an antisense oligonucleotide. 19. The compound of claims 18 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 20. The compound of claim 19 wherein the modified internucleoside linkage is a phosphorothioate linkage. 21. The compound of claim 18 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 22. The compound of claim 21 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 23. The compound of claim 18 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 24. The compound of claim 23 wherein the modified nucleobase is a 5-methylcytosine. 25. The compound of claim 18 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 26. A composition comprising the compound of claim 17 and a pharmaceutically acceptable carrier or diluent. 27. The composition of claim 26 further comprising a colloidal suspension system. 28. The composition of claim 26 wherein the compound is an antisense oligonucleotide. 29. A method of inhibiting the expression of TERT in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 17 so that expression of TERT is inhibited. 30. A method of modulating apoptosis in a cell comprising contacting said cell in vitro with the compound of claim 17 whereby apoptosis is modulated. 31. A method of inhibiting cell growth comprising contacting cells in vitro with the compound of claim 17 whereby the growth of cells is inhibited. 32. The method of claim 17 wherein said cells are cancer cells. 